Some genetics experts felt the event raised awareness of the importance of testing, while others had mixed feelings amid ...

The firm voluntarily retracted the BLA amid an effort to reprioritize its pipeline and is looking for partners to advance the program.

The partners aim to retrospectively identify predictive and prognostic breast cancer biomarkers using data from multiple randomized trials.

The firm said it expects a loss of ¥58.0 billion by discontinuing development its cell therapies, which are currently in preclinical phase.

The firm's lead candidate is a preclinical gene therapy for dry AMD, which it is advancing into IND-enabling studies.

NEW YORK – Sapienza University, Takis Biotech, and liquid biopsy company Tethis said on Friday they are teaming up to develop HER3-targeted therapies and companion diagnostics for lung cancer, with ...

Galapagos is collecting bids for its cell therapy business, and its board will announce its decision on selling the business by Nov. 5.

The firm will use the funding to launch its T-cell engager candidate into clinical trials early next year in LY6G6D-expressing colorectal cancer.

The drugmaker has launched an international Phase I trial, dubbed Breakfree-2, in seven countries to test the autologous therapy.

Investigators are assessing whether treatment with the angiotensinogen-targeting RNAi agent reduces patients' risk of cardiovascular disease.

The study found that patients with luminal B subtype prostate cancer benefited from the addition of hormone therapy to ...

The drugmaker is transitioning to Trialbee's Honey platform to better screen patients, including for biomarker information, ...